文献速递妇科

CIN后接种HPV疫苗与后续宫颈癌风险的回顾性队列研究

Human papillomavirus vaccination following cervical intraepithelial neoplasia and subsequent cervical cancer: A retrospective propensity score-matched cohort study.
PubMed 文献 · Gynecol Oncol · 2026-10-31

基于TriNetX全球协作网络的回顾性队列研究,纳入2020-2022年诊断为CIN且定期宫颈筛查的患者,按后续HPV疫苗接种记录进行倾向性评分匹配。匹配后每组7397例,分析显示接种组宫颈癌诊断少于未接种组(HR 0.56,95%CI 0.39-0.79;p=0.001),CIN3亚组关联显著(HR 0.32),CIN1-2亚组无显著关联。

要点

  • CIN后记录接种HPV疫苗与后续宫颈癌诊断减少相关(HR 0.56)。
  • CIN3患者中关联显著(HR 0.32),CIN1-2患者中无显著关联。
  • 研究为回顾性设计,暴露错分与残余混杂限制因果解释。

核心结论

  • 记录的HPV疫苗接种与总体及CIN3患者后续宫颈癌诊断减少相关。
  • CIN1-2患者中未观察到显著关联。
  • 因暴露错分、残余混杂等因素,不能作因果推断。

研究设计与样本

  • 回顾性队列研究,使用TriNetX全球协作网络数据。
  • 纳入2020-2022年诊断CIN并接受定期宫颈筛查的患者,按后续HPV疫苗接种记录分组。
  • 采用倾向性评分匹配,匹配变量包括人口学特征、选定诊断和宫颈操作。
  • 匹配后每组7397例,排除结局相关病例后疫苗组7194例、对照组7233例。
  • 评估CIN诊断后第1天至第3年的结局,排除诊断前已记录宫颈癌的患者。

主要发现

  • 疫苗组47例宫颈癌诊断,对照组92例(HR 0.56,95%CI 0.39-0.79;p=0.001)。
  • CIN3亚组中关联显著(HR 0.32;95%CI 0.20-0.53;p<0.001)。
  • CIN1-2亚组中无显著关联(HR 0.98;95%CI 0.51-1.92;p=0.96)。

临床怎么用

  • 对于CIN患者,尤其是CIN3患者,记录HPV疫苗接种史可能有助于降低后续宫颈癌风险。
  • 需结合共享决策,向CIN患者说明观察性研究提示的关联及因果推断局限性。

局限性

  • 暴露错分可能影响结果。
  • 存在残余混杂。
  • 差异观察可能偏倚结果。
  • 非比例风险限制因果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the association between human papillomavirus (HPV) vaccination following cervical intraepithelial neoplasia (CIN) and subsequent invasive cervical cancer (CC) diagnoses. METHODS: We conducted a retrospective cohort study using the TriNetX Global Collaborative Network. Patients diagnosed with CIN (ICD-10-CM: N87, N87.0, N87.1, D06) during 2020-2022 who underwent regular cervical screening (Z12.4) were compared according to subsequent HPV vaccination records. Propensity score matching (PSM) incorporated demographic characteristics, selected diagnosis, and cervical procedures. Outcomes were assessed for day 1 through year 3 after the CIN diagnosis. Patients with CC recorded before diagnosis were excluded. Exploratory analyses evaluated code-defined CIN1-2 and CIN3 subgroups. RESULTS: Matching yielded 7397 patients per cohort. After outcome-specific exclusions, 7194 vaccinated patients and 7233 comparators remained, with 47 and 92 CC diagnoses, respectively (HR 0.56, 95% CI 0.39-0.79; p=0.001). By CIN grade, a significant association was observed in CIN3 patients (HR 0.32; 95% CI 0.20-0.53; p < 0.001), but not CIN1-2 patients (HR 0.98; 95% CI 0.51-1.92; p=0.96). CONCLUSIONS: Recorded HPV vaccination was associated with fewer CC diagnosis overall and in CIN3 patients. Exposure misclassification, residual confounding, differential observation, and non-proportional hazards limit casual interpretation.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Farolfi A, Casadei C, Strada I, et al. Human papillomavirus vaccination following cervical intraepithelial neoplasia and subsequent cervical cancer: A retrospective propensity score-matched cohort study. Gynecol Oncol. 2026. PMID: 42966333. doi:10.1016/j.ygyno.2026.10.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。